exactly. The need for efficiency in developing effective new therapeutics has never been greater.

Size: px
Start display at page:

Download "exactly. The need for efficiency in developing effective new therapeutics has never been greater."

Transcription

1

2 exactly. The need for efficiency in developing effective new therapeutics has never been greater. As demands on the global healthcare system increase and treating disease becomes more complex, the research, discovery and development of new therapeutics has never been more important. Now more than ever, Charles River is committed to developing broader, more flexible relationships with our clients, providing tailored approaches to help accelerate and support research into the understanding of disease and the development and delivery of safe and effective new therapies. resources with the changing needs of a complex product development portfolio. With our global network of resources, high-quality products and services, state-of-the-art facilities and our expert staff, we are building a portfolio that provides exactly what our clients need to support their research programs. Our goal is to help accelerate research and drug development programs. Exactly. Our relationships with clients are evolving into strategic partnerships as we aim to become an extension of their internal organizations. From primary research through proof-of-concept, we deliver the capabilities and expertise needed to help balance their internal Our clients are facing a time of unprecedented change. The pressure to produce new, highly effective therapies more cost-efficiently, while meeting safety and regulatory requirements, has never been greater. By strategically supporting our clients with a unique portfolio of products, services, facilities and scientific expertise, we believe we can be part of the solution, partnering with them to accelerate drug development. Researchers are expanding their relationships with Contract Research Organizations like Charles River to help accelerate new compounds efficiently from discovery through the drug development continuum. JAMES C. FOSTER, CHAIRMAN, PRESIDENT AND CEO charles river 1 2

3 discover. With new technologies and an increasing understanding of the complexities of health and disease comes the opportunity to discover innovative therapeutics. Research and discovery requires innovation and flexibility at every stage. The appropriate use of models to identify a target, characterize compound disposition, determine a pathway or mimic a disease is essential to the discovery process. For more than half a century, Charles River has supported primary research needs, pioneering rigorous and exacting standards for animal production including strict biosecurity measures that ensure that our clients around the world receive reliable, predictive models. The key to rapid decision-making lies in high-quality assessment, rapid data availability and analytical expertise. We offer in vitro assays, in vivo screening tools, extensive xenograft and imaging capabilities and laboratory support services to help define and optimize lead candidates prior to the preclinical phase and the costly safety testing required for early-phase clinical trials. With extensive experience in research models, pharmacology and toxicology, combined with unmatched expertise in veterinary science, Charles River provides a high-quality customized approach to support research and discovery programs. Capabilities designed to help accelerate research and discovery: Research Models Discovery and Imaging Services Genetically Engineered Models and Services Surgical Services Research Animal Diagnostic Services Custom Antibody Production We are continually expanding our portfolio to provide comprehensive integrated services that align with our clients program needs and support researchers with the characterization and optimization of lead compounds. charles river 3 4

4 integrate. As newly discovered compounds move through the development process into the clinical phase and then to market, there is a critical need to balance efficacy assessment and patient safety with reduced cycle times. Whether in a single aspect of a study or through a full discoveryto-ind program, our scientists have the expertise to flexibly support and expedite all elements of preclinical work. We can assist with appropriate species selection, pre-ind consultation and toxicology and safety pharmacology study design approaches, supported by extensive laboratory services. and enhance the process, allowing maximum optimization of both internal and external resources and supporting the safe and effective acceleration of compounds through the drug development process. Our team is experienced in designing and conducting pilot and GLPcompliant general and specialty toxicology studies for a variety of compound types. Our involvement in clients preclinical programs allows us to aid in the seamless transition of a compound into Phase I clinical trials. Our consulting and regulatory experts can customize unique programs to navigate from preclinical into clinical development. Broad-based programs complement clients core competencies In addition, our early clinical development experience can aid in appropriate study design, stringent safety assessment and effective participant recruiting, ensuring that participant safety is a priority. Support to safely accelerate drug development: Safety Assessment Broad Specialty Toxicology Experience Early-Phase Clinical Trials Clinical Trial Support Services Therapeutic Area Expertise Regulatory Consulting We can help design and conduct studies to ensure the most efficient use of resources while delivering effective safety assessment programs from preclinical through first-in-human (FIH) clinical trials and beyond. charles river 5 6

5 accelerate. Rapidly obtaining the most accurate and reliable results is essential for safe and efficient quality control and manufacturing. The increasing number of novel biologics in development creates new challenges in the types of testing required to assess the manufacturing process, including the complexities of safety, potency and lot release testing. With a focus on regulatory guidelines, Charles River offers proven testing solutions and programs designed to address each step in the product manufacturing process. Rapid, reliable endotoxin test results are necessary to confirm the timely and safe manufacture of all injectable drugs and implantable devices, and the application of dialysis as well as cellular and nuclear therapeutics. As an extension of our trusted routine LAL testing products, our FDA-licensed Endosafe -PTS is an innovative handheld test system that provides quantitative results in just 15 minutes, with the convenience of portability. The new Endosafe -MCS system offers a complementary highervolume solution for laboratory settings. To meet the research and development needs of clients focused on virus and vaccine production, Charles River offers a comprehensive portfolio of avian products and testing services, including the specific pathogen-free egg. We also provide comprehensive testing, process validation and vaccine manufacturing services to help clients around the world develop and market biopharmaceutical therapies. Our services enable companies to meet regulatory guidelines and ultimately bring their products to market faster and more economically. Supporting our clients quality and manufacturing needs to ensure accurate and reliable results: Avian Products and Services Endotoxin and Microbial Detection Products and Services Biopharmaceutical Services, including: viral clearance, vaccine safety and manufacturing, cell line characterization and cell banking, in vivo biosafety and potency testing, bioassay development We support our clients quality and manufacturing needs through innovative services, products and solutions for in-process and final release testing of drugs, devices and vaccines. charles river 7 8

6 optimize. Expertise, experience, insight, flexible availability of resources exactly what is needed to support efficient research and drug development. Optimizing programs and maximizing resources are essential for today s research and development climate. Precise planning helps clients anticipate and navigate through the many challenges that can adversely affect research, delay development and cause unnecessary expenditure, and even ultimately prevent products from reaching their full market potential. These challenges may be related to animal care activities, drug safety, dose regimen, clinical planning or fundamental strategic approaches to program design. To help anticipate and overcome these hurdles, Charles River offers a range of consulting options and resources, including strategic assistance, regulatory and scientific advice, individualized program management, contract staffing within clients facilities and also veterinary care training. the experience, insight and knowledge necessary to help clients reach strategic milestones. This wealth of experience encompasses multiple disciplines, compound classes and therapeutic areas, enabling clients to leverage this expertise to manage a facility, design and direct focused research and development programs and prepare regulatory documents in a timely and efficient manner. Our goal is to provide exactly what our clients need to fully leverage their core competencies and extend their internal resources by flexibly utilizing ours. Optimizing programs and maximizing resources are essential for today s research and development climate. Our global network of scientific, regulatory and veterinary professionals and highly trained animal caretakers all possess Resources, experience and expertise to enhance our clients capabilities: Consulting and Staffing Services IND/Global Regulatory Consulting Program Management and Strategic Consulting Educational Programs charles river 9 10

7 commitment. The quality of our lives can be impacted by the quality of theirs. Humane care is not only a moral imperative, but a scientific necessity. Research animal models are an important resource that enables us to further our knowledge of living systems and contribute to the discovery and delivery of life-saving drugs and procedures for both humans and animals. In addition to the role we play in helping improve human health, we offer a full range of services to support development of products for animal health. We also continue to seek innovative ways to provide effective testing without relying on traditional research models. Charles River also implemented a global Humane Care Initiative nearly ten years ago. Going beyond the requirements set forth in global, federal and international regulations, this initiative raises awareness of the importance of humane care. Through effective orientation and training, we continually reinforce this culture of caring that has been a passion of Charles River employees for more than 60 years. Treating animals with care and respect can also directly influence the success of a research protocol. For decades we have fostered this culture across our company and around the globe to establish ourselves as a worldwide leader in the compassionate care of research animals. This concern for animal welfare is expressed in one of our core values: We are committed to the humane care of the research animals produced and used in all Charles River activities. As animal caregivers and researchers, we are all responsible for the health and well-being of the animals in our care. charles river 11 12

8 Market Approval NDA/BLA/MAA Submission IND/CTA Filing From the global standardization of our research models to the high standards that we set for our professional team and our state-of-the-art facilities and technologies, we can customize programs to meet the specific research needs of our clients. The Charles River portfolio of capabilities supports primary research and spans each phase of the drug discovery and development process. The breadth and depth of our portfolio allows for the customization of solutions, enabling clients to reduce costs, enhance productivity and increase speed to market, all with the convenience of working with one reliable partner. As pressure for efficiency increases, outsourcing non-core activities can alleviate internal bottlenecks and align internal resources with immediate needs, allowing clients to focus on proprietary drug discovery and go-to-market efforts. In the academic sector, Charles River remains strongly committed to supporting high-quality research through our globally exactly. standardized models and health surveillance programs, as well as our continuing technical support, and veterinary science and animal husbandry training. With approximately 70 facilities in 17 countries, Charles River aims to be the ideal partner for progressing new therapies from research models to humans in a rational, cost-effective and timely manner. Understanding our clients needs for global standards and compliance, flexible resources and a competent partner, we continue to invest in and expand our portfolio of technologies and resources to add the scientific expertise and capacity needed to support the efficient acceleration of drug development. Global Support for Research and Integrated Drug Development RESEARCH MODELS SERVICES FOR RESEARCH MODELS DISCOVERY, IMAGING AND PRECLINICAL SERVICES CLINICAL SERVICES EARLY RESEARCH Research Models Laboratory Animal Equipment PRECLINICAL DEVELOPMENT Research Animal Diagnostic Services Consulting and Staffing Services Genetically Engineered Models and Services Preconditioning Services Functional and Anatomical Imaging In Vitro and In Vivo Screening Lead Optimization Pharmacology Pharmacokinetics / ADME Pharmacodynamics / Biomarkers Safety Pharmacology IND Enabling Toxicology Genetic Toxicology Pathology Services Bioanalytical Services Strategic / Regulatory Consulting PHASE 0/I Early-Phase Clinical Trials Central Laboratory Clinical Bioanalysis Data Management and Biostatistics CLINICAL TRIALS Subchronic / Chronic Toxicology MARKET PHASE II PHASE III PHASE IV Developmental and Reproductive Toxicology Carcinogenicity Studies BIOPHARMACEUTICAL AND VACCINE SUPPORT SERVICES IN VITRO DETECTION SYSTEMS Viral Safety Vaccine Safety and Manufacturing Cell Line Banking and Characterization Potency, Stability, Bioassay Development In Vivo Biosafety Avian Products and Services Endotoxin and Microbial Detection Products and Services charles river 13 14

9 CRIVER-1 International Toll-Free:

Pharmacology skills for drug discovery. Why is pharmacology important?

Pharmacology skills for drug discovery. Why is pharmacology important? skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th

More information

BIOTECHNOLOGY OPERATIONS

BIOTECHNOLOGY OPERATIONS BIOTECHNOLOGY OPERATIONS Principles and Practices Michael J. Roy TECHNISCHE INFORMATION SBIBLIOTHEK UNIVERSITATSBIBLIOTHEK HANNOVER CRC Press TaylorStFrancis Croup Boca Raton London New York CRC Press

More information

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise

The NIH Roadmap: Re-Engineering the Clinical Research Enterprise NIH BACKGROUNDER National Institutes of Health The NIH Roadmap: Re-Engineering the Clinical Research Enterprise Clinical research is the linchpin of the nation s biomedical research enterprise. Before

More information

From The Lab To Your Medicine Cabinet:

From The Lab To Your Medicine Cabinet: From The Lab To Your Medicine Cabinet: A Pharmaceutical Drug s Journey Presented by: Dr. Steven Hansel Sr. Director; Pfizer Moderated by: Sam Gilchrist Ph.D. Candidate; UBC The Drug Development Process

More information

POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics.

POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics. POLICY AND PROCEDURES OFFICE OF NEW DRUGS Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics Table of Contents PURPOSE...1 BACKGROUND...2 POLICY...3 ROLES AND RESPONSIBILITIES...4

More information

DMPK: Experimentation & Data

DMPK: Experimentation & Data DMPK: Experimentation & Data Interpretation Mingshe Zhu, Mike S. Lee, Naidong Weng, and Mark Hayward Prerequisite: Entry-level scientists with hands on experience in LC/MS as well as advanced students

More information

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit?

Issues. Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? ELLEN PURÉ, Ph.D. Issues Does the academe have as a goal or an obligation, the development of its discoveries for human benefit? Can the academic review process support individual career development in

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 23 July 1998 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL

More information

PPD LABORATORIES CENTRAL LAB: SUPERIOR SERVICE, QUALITY DATA WITHOUT COMPROMISES

PPD LABORATORIES CENTRAL LAB: SUPERIOR SERVICE, QUALITY DATA WITHOUT COMPROMISES PPD LABORATORIES CENTRAL LAB: SUPERIOR SERVICE, QUALITY DATA WITHOUT COMPROMISES PPD Laboratories provides world-class scientific expertise with state-of-the-art technologies supported by a commitment

More information

Regulatory Issues in Genetic Testing and Targeted Drug Development

Regulatory Issues in Genetic Testing and Targeted Drug Development Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types

More information

CLINICAL DEVELOPMENT OPTIMIZATION

CLINICAL DEVELOPMENT OPTIMIZATION PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP

More information

Mayo Central Laboratory for Clinical Trials A Division within Mayo Clinical Trial Services

Mayo Central Laboratory for Clinical Trials A Division within Mayo Clinical Trial Services Mayo Central Laboratory for Clinical Trials A Division within Mayo Clinical Trial Services LABORATORY TESTING SERVICES YOUR PARTNER IN LABORATORY MEDICINE The key note of progress in the 20th century is

More information

Global regulatory affairs role in the biopharmaceutical industry

Global regulatory affairs role in the biopharmaceutical industry CHAPTER TWO Global affairs role in the biopharmaceutical industry 2.1 Overview 2.2 Global affairs organization 2.3 Role of global affairs 2.4 Key functions and activities 2.5 Global strategy 2.6 Global

More information

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013 Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory

More information

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Overview of Phase 1 Oncology Trials of Biologic Therapeutics Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of

More information

SERVICES FOR. Devices and Combination Products

SERVICES FOR. Devices and Combination Products SERVICES FOR Devices and Combination Products How to Contact Us U.S. FACILITIES / CLIENT SERVICES St. Paul 2540 Executive Drive St. Paul, MN 55120 FAX 651.675.2005 Atlanta 1265 Kennestone Circle Marietta,

More information

Quality by Design Concept

Quality by Design Concept 3rd Jerusalem Conference on Quality and Pharma Sciences 6-7 June, 2012 QbD in Clinical Research - Where Can QbD Impact Clinical Research Practices? Dr. Yafit Stark Vice President, TEVA Pharmaceutical Industries,

More information

Call 2014: High throughput screening of therapeutic molecules and rare diseases

Call 2014: High throughput screening of therapeutic molecules and rare diseases Call 2014: High throughput screening of therapeutic molecules and rare diseases The second call High throughput screening of therapeutic molecules and rare diseases launched by the French Foundation for

More information

Tuberculosis OUR MISSION THE OPPORTUNITY

Tuberculosis OUR MISSION THE OPPORTUNITY Tuberculosis OUR MISSION Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. Our Global Health Program is

More information

Lilly Covance Strategic Alliance From Vision to Results. Adrienne Takacs, PhD Jonathan Koch, MBA

Lilly Covance Strategic Alliance From Vision to Results. Adrienne Takacs, PhD Jonathan Koch, MBA Lilly Covance Strategic Alliance From Vision to Results Adrienne Takacs, PhD Jonathan Koch, MBA Topics 1. Lilly s Challenge... a Partnership Opportunity 2. Our Landmark Agreement 3. A Local Success Story

More information

Overview of Drug Development: the Regulatory Process

Overview of Drug Development: the Regulatory Process Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

4.1 Objectives of Clinical Trial Assessment

4.1 Objectives of Clinical Trial Assessment L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical

More information

NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997

NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997 NATIONAL HEALTH COUNCIL RESOLUTION Nº 251, DATED 7 AUGUST 1997 Plenary of the National Health Council in its 15 th Special Meeting, held on 5 August 1997, in the exercise of its competencies, as set forth

More information

We design talent strategies that accelerate business outcomes.

We design talent strategies that accelerate business outcomes. 1 We design talent strategies that accelerate business outcomes. Where there are critical gaps, we build talent from within and attract new talent from the outside. At every level of the enterprise, we

More information

Technology and Expertise Add Operational Value to Medical Device Trials

Technology and Expertise Add Operational Value to Medical Device Trials Technology and Expertise Add Operational Value to Medical Device Trials Copyright 2015 Medidata Solutions. Medidata Solutions and other trademarks reserved in the US and globally. Medidata and other marks

More information

BEST PRACTICES RESEARCH

BEST PRACTICES RESEARCH 2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost

More information

Non-clinical development of biologics

Non-clinical development of biologics Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service

More information

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH

Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH Manufacturing CUSTOM CHEMICALS AND SERVICES, SUPPORTING SCIENTIFIC ADVANCES FOR HUMAN HEALTH VWR enables the advancement of science by providing high-quality chemicals and services, customized to your

More information

Basic Overview of Preclinical Toxicology Animal Models

Basic Overview of Preclinical Toxicology Animal Models Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background

More information

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company

More information

Apply with Resume to: www.rjrt.com Submenu Path Company/Careers/Current Openings/Job Type: Science

Apply with Resume to: www.rjrt.com Submenu Path Company/Careers/Current Openings/Job Type: Science Position: Biostatistician Required Experience: At least 5 years This position is responsible for providing broad statistical support in general and biostatistical support specifically, including study

More information

Cell Discovery 360: Explore more possibilities.

Cell Discovery 360: Explore more possibilities. Cell Discovery 360: Explore more possibilities. Flexible solutions for the BioPharma laboratory Blood Banking Capillary Electrophoresis Centrifugation Flow Cytometry Genomics Lab Automation Lab Tools Particle

More information

Testing Services for Large Molecule Drug Development

Testing Services for Large Molecule Drug Development Testing Services for Large Molecule Drug Development Our mission is to extend our clients capabilities by combining scientific knowledge, capacity, regulatory expertise and flexibility to provide the trusted,

More information

Approximate cost of a single protocol amendment: $450,000

Approximate cost of a single protocol amendment: $450,000 Insight brief 34% of protocol amendments are avoidable Approximate cost of a single protocol amendment: $450,000 Improving clinical development in emerging biopharma settings: How model based drug development

More information

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.

HSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works. November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also

More information

Clinical trials preclinical requirements. Clinical trials - legislation

Clinical trials preclinical requirements. Clinical trials - legislation Clinical trials preclinical requirements Mikael Andersson, PhD Senior Expert Medical Products Agency, Sweden Tallinn 9/10 2009 Clinical trials - legislation Directive 2001/20/EC Clinical trial directive

More information

An information platform that delivers clinical studies better, faster, safer and more cost effectively

An information platform that delivers clinical studies better, faster, safer and more cost effectively An information platform that delivers clinical studies better, faster, safer and more cost effectively Powering Process & Performance Proactively manage study start-up and execution Risk profile new sites

More information

U.S. Food and Drug Administration Center for Devices and Radiological Health REGULATORY SCIENCE PRIORITIES (FY2016)

U.S. Food and Drug Administration Center for Devices and Radiological Health REGULATORY SCIENCE PRIORITIES (FY2016) U.S. Food and Drug Administration Center for Devices and Radiological Health REGULATORY SCIENCE PRIORITIES (FY2016) Executive Summary October 20, 2015 The Regulatory Science Subcommittee (RSS) of the CDRH

More information

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

More information

OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies

OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies OCT Practical Aspects of Conducting Clinical Trials for Russian Innovative Companies Innovative Drug Research and Development in Russia 2012 OCT: CRO in Russia, Central and Eastern Europe Russian Innovative

More information

Technology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)

Technology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com) M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over

More information

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD

BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD BioWorld s PARTNER in FOCUS: Covance AN ADVERTISING SERVICE FROM BIOWORLD PARTNERING Trend Allows Smart CROs TO Provide Gamut of Services TO Any Size COMPANy Five years ago, contract research organizations

More information

Guidance for Industry

Guidance for Industry Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center

More information

Pharmaceutical Sciences

Pharmaceutical Sciences Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

Preclinical Support Services

Preclinical Support Services Preclinical Support Services Expert toxicology solutions providing consultation, study design testing and site monitoring to ensure a seamless transition of projects through IND-enabling studies and into

More information

Quality and Safety Evaluation of Gene Therapy Products in Japan

Quality and Safety Evaluation of Gene Therapy Products in Japan Quality and Safety Evaluation of Gene Therapy Products in Japan Review Mechanism for Gene Therapy in Japan The review mechanism for gene therapy in Japan was partially amended to simplify the necessary

More information

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents

Is a Career in the. Pharmaceutical. Check out our online Student Center to find out more: www.aaps.org/forstudents Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right

More information

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS

More information

PharmD Postdoctoral Fellowship Program

PharmD Postdoctoral Fellowship Program Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the

More information

The Clinical Trials Process an educated patient s guide

The Clinical Trials Process an educated patient s guide The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

Medical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering

Medical Device Solutions. Battelle. Applied Research Device Development Clinical Research Sustaining Engineering Medical Device Solutions Battelle Applied Research Device Development Clinical Research Sustaining Engineering 0 2 Overview Applied Research Device Development Clinical Research Sustaining Engineering

More information

Guidance for Industry

Guidance for Industry Guidance for Industry End-of-Phase 2A Meetings U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 Procedural Guidance

More information

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis

CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis CDRD and the MSSC Seek Collaborative Projects to Discover and Develop New Treatments for Progressive Multiple Sclerosis The Centre for Drug Research and Development (CDRD) and the Multiple Sclerosis Society

More information

Review of CBER's Current and Planned Post-marketing Safety Practices

Review of CBER's Current and Planned Post-marketing Safety Practices Review of CBER's Current and Planned Post-marketing Safety Practices Robert Ball MD, MPH, ScM Director, Office of Biostatistics and Epidemiology (OBE), Center for Biologics Evaluation and Research (CBER),

More information

FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE

FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration

More information

Strategic Consulting Services

Strategic Consulting Services Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief

More information

Effective Outsourcing of Clinical Pharmacology Studies in Europe. John Horkulak Executive Director, Eurasian External Clinical Study Operations

Effective Outsourcing of Clinical Pharmacology Studies in Europe. John Horkulak Executive Director, Eurasian External Clinical Study Operations Effective Outsourcing of Clinical Pharmacology Studies in Europe John Horkulak Executive Director, Eurasian External Clinical Study Operations Key Questions Do clinical pharmacology studies require a different

More information

Challenges in the Regulation of Pediatric Clinical Trials

Challenges in the Regulation of Pediatric Clinical Trials Challenges in the Regulation of Pediatric Clinical Trials Wilson W. Bryan, M.D. FDA / CBER / OCTGT wilson.bryan@fda.hhs.gov National Institutes of Health Recombinant DNA Advisory Committee (RAC) Meeting

More information

Mayo Alliance for Clinical Trials

Mayo Alliance for Clinical Trials Mayo Alliance for Clinical Trials A Division within Mayo Clinical Trial Services PROFESSIONAL CLINICAL TRIALS SERVICES ADVANCING PATIENT CARE THROUGH SCIENTIFIC DISCOVERY It is a great thing to make scientific

More information

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective

Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food

More information

Electronic Study Management

Electronic Study Management Electronic Study Management New Tools for Improving the Efficiency of Pre-Clinical R&D Published in Scientific Computing January 2006 Michael H Elliott Back in the late 1970s, I was working in a biology

More information

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Session 6 Clinical Trial Assessment Phase I Clinical Trial L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

INVESTIGATOR PROFILE: Heather DeLoid, DVM

INVESTIGATOR PROFILE: Heather DeLoid, DVM INVESTIGATOR PROFILE: Heather DeLoid, DVM Meet Heather DeLoid, DVM Heather DeLoid, DVM, joins Preclinical Translational Services of Wake Forest Innovations as its new Associate Surgical Research Veterinarian.

More information

Graduate Program Objective #1 Course Objectives

Graduate Program Objective #1 Course Objectives 1 Graduate Program Objective #1: Integrate nursing science and theory, biophysical, psychosocial, ethical, analytical, and organizational science as the foundation for the highest level of nursing practice.

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Codevelopment of Two or More New Investigational Drugs for Use in Combination U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences

Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences Discover more, discover faster. High performance, flexible NLP-based text mining for life sciences It s not information overload, it s filter failure. Clay Shirky Life Sciences organizations face the challenge

More information

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer

More information

Biological importance of metabolites. Safety and efficacy aspects

Biological importance of metabolites. Safety and efficacy aspects Biological importance of metabolites Safety and efficacy aspects Bernard Walther Technologie Servier Biological importance of metabolites Safety testing of drug metabolites Bioanalytical strategy Structural

More information

H y B rid i Z ation- elis a. elis a. Bioanalytical o verview. ecl

H y B rid i Z ation- elis a. elis a. Bioanalytical o verview. ecl lc- icp-ms lc-ms/ms G yros H y B rid i Z ation- elis a elis a Bioanalytical o verview ecl icp-ms Bioanalytical Overview One of the world s largest offerings for bioanalysis of small molecules and biologics,

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld

LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO. @LSQld LIFE SCIENCES QUEENSLAND LIMITED (LSQ) Mario Pennisi CEO @LSQld LEADING DESTINATION FOR CLINICAL RESEARCH INVESTORS IN QLD INCLUDE: LIFE SCIENCES IN QLD ~300 companies in life sciences ~$5B invested by

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

CTC Technology Readiness Levels

CTC Technology Readiness Levels CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.

More information

Careers in Laboratory Animal Science. Elton Machholz, Lisa Ngaymsa & Miriam Rose Consulting & Staffing Services Division Germantown, MD

Careers in Laboratory Animal Science. Elton Machholz, Lisa Ngaymsa & Miriam Rose Consulting & Staffing Services Division Germantown, MD Careers in Laboratory Animal Science Elton Machholz, Lisa Ngaymsa & Miriam Rose Consulting & Staffing Services Division Germantown, MD Backgrounds Miriam Rose BS Animal/Veterinary Science West Virginia

More information

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY

OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY NINESIGMA WHITE PAPER OPEN INNOVATION STRATEGIES IN THE HEALTHCARE INDUSTRY How six leading healthcare companies are leveraging Open Innovation to achieve their innovation goals By: Stephen Clulow, Director

More information

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES Guideline Title Radiopharmaceuticals based on Monoclonal Antibodies Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC

More information

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia Medicines for Neglected Diseases Workshop Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia September 11, 2010 Poverty, Many People Poor health conditions High Morbidity

More information

through advances in risk-based

through advances in risk-based Insight brief Quintiles is a market leader with >100 risk-based monitoring studies Quintiles developed solutions that bring as much as 25% cost reduction over traditional trial execution approaches Transform

More information

Catalent Biologics & Clinical Supplies The SMART Solution

Catalent Biologics & Clinical Supplies The SMART Solution Catalent Biologics & Clinical Supplies The SMART Solution Advanced Technology and Integrated Solutions From DNA to Clinical Supply & Cold Chain Distribution Dr. Florian Schwaak Account Manager Germany

More information

GLOBAL CORPORATE SERVICES

GLOBAL CORPORATE SERVICES GLOBAL CORPORATE SERVICES ALIGNING CBRE s Global Corporate Services (GCS) is the world leader in commercial real estate services. As the top real estate services provider named to the Global Outsourcing

More information

Transforming study start-up for optimal results

Transforming study start-up for optimal results Insight brief Transforming study start-up for optimal results A holistic, data-driven approach integrating technology, insights and proven processes to position clinical trials for ultimate success Up

More information

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information

More information

Guidance for Industry Safety Testing of Drug Metabolites

Guidance for Industry Safety Testing of Drug Metabolites Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

Performance Profile. Clinical Study Physician. www.celyad.com 1

Performance Profile. Clinical Study Physician. www.celyad.com 1 Performance Profile Clinical Study Physician www.celyad.com 1 Role: Provide medical guidance and leadership throughout the development and conduct of clinical trials. You will be responsible for overseeing

More information

MEDICAL DEVICE & DIAGNOSTICS

MEDICAL DEVICE & DIAGNOSTICS to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,

More information

Novartis Investigator Initiated Trials (IITs) Guidelines

Novartis Investigator Initiated Trials (IITs) Guidelines Novartis Investigator Initiated Trials (IITs) Guidelines Introduction and background As part of our commitment to delivering innovative therapies to patients worldwide, Novartis believes in the need to

More information

Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update

Kentucky Lung Cancer Research Program. 2010 Strategic Plan Update Kentucky Lung Cancer Research Program 2010 Strategic Plan Update Approved by the KLCR Program Governance Board August 12, 2009 KLCR Program Strategic Plan Table of Contents Introduction... 3 GOAL 1: Investigator-Initiated

More information

From Research Services and Process Development to GMP Manufacturing

From Research Services and Process Development to GMP Manufacturing From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development

More information

Once a new drug is discovered, there is a specific series of steps it must go through to acquire FDA approval. Before any applications are sent to the

Once a new drug is discovered, there is a specific series of steps it must go through to acquire FDA approval. Before any applications are sent to the Research Primer: Introduction to the FDA Drug Approval Process and Off Label Use BRITTANY LA COUTURE OCTOBER 22, 2015 Introduction The United States is home to the majority of the world s new drug developers.

More information

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;

More information

Regulatory Submission: Applying GLP in Surgical Efficacy Studies

Regulatory Submission: Applying GLP in Surgical Efficacy Studies Regulatory Submission: Applying GLP in Surgical Efficacy Studies Curtis Schondelmeyer, DVM Director Preclinical Veterinary Services and Efficacy and Surgical Research Services Welcome to Toxikon 2 CONFIDENTIAL

More information

Rochester BioVenture Center November 14th

Rochester BioVenture Center November 14th Rochester BioVenture Center November 14th Calvert Holdings, Inc. Established in 1996 Parent company for several subsidiaries Focus: health care services and investments Corporate HQ located in Cary, NC

More information

Global Contract Research Organization (CRO) Industry: Overview and Trends, 2008

Global Contract Research Organization (CRO) Industry: Overview and Trends, 2008 A Service of Indigo Research A Cipher www.indigoresearch.com Global CRO Market 2005- $15 Billion Global Contract Research Organization (CRO) Industry: Overview and Trends, 2008 Published April 2008 CRO

More information

From cells to therapeuticsvivalis. Humalex Fully human antibody discovery platform An integrated therapeutic development offering

From cells to therapeuticsvivalis. Humalex Fully human antibody discovery platform An integrated therapeutic development offering From cells to therapeuticsvivalis Humalex Fully human antibody discovery platform An integrated therapeutic development offering Humalex from bench-top to clinical development The Humalex platform enables

More information

Access. Action. Insight. Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions

Access. Action. Insight. Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions Cardinal Health Specialty Solutions Healthcare Analytics and Marketing Communications Consultative, Analytical, and Promotional Solutions Access Action Insight In today s increasingly competitive healthcare

More information